✦ LIBER ✦

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

✍ Scribed by Monique J. Bijl; Ron H. N. van Schaik; Laureen A. Lammers; Albert Hofman; Arnold G. Vulto; Teun van Gelder; Bruno H. Ch. Stricker; Loes E. Visser

Publisher: Springer US
Year: 2009
Tongue: English
Weight: 207 KB
Volume: 118
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-008-0272-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of CYP2D6 polymorphisms in tamoxi

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment

✍ T. Ramón y Cajal; A. Altés; L. Paré; E. del Rio; C. Alonso; A. Barnadas; M. Baig 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 177 KB

Prevalent breast cancer patients with a

Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users

✍ A. S. Dieudonné; D. Lambrechts; B. Claes; T. Vandorpe; H. Wildiers; D. Timmerman 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 224 KB

Comprehensive CYP2D6 genotype and adhere

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

✍ Alastair M. Thompson; Andrea Johnson; Philip Quinlan; Grantland Hillman; Marcel 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 321 KB

Concurrent use of tamoxifen with CYP2D6

Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

✍ Laurent Azoulay; Sophie Dell’Aniello; Laetitia Huiart; Guillaume Galbaud du Fort 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 207 KB

Potent CYP2D6 Inhibiting drugs do not in

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

✍ Nava Siegelmann-Danieli; Daniel Kurnik; Yossi Lomnicky; Janet Vesterman-Landes; 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 170 KB

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Matthew Goetz; Vera Suman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions